Insulet

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. 

CEO
Ashley A. McEvoy
CEOAshley A. McEvoy
Employees
3,900
Employees3,900
Headquarters
Acton, Massachusetts
HeadquartersActon, Massachusetts
Founded
2000
Founded2000
Employees
3,900
Employees3,900

PODD Key Statistics

Market cap
17.73B
Market cap17.73B
Price-Earnings ratio
74.46
Price-Earnings ratio74.46
Dividend yield
Dividend yield
Average volume
1.22M
Average volume1.22M
High today
$258.75
High today$258.75
Low today
$249.63
Low today$249.63
Open price
$255.83
Open price$255.83
Volume
945.55K
Volume945.55K
52 Week high
$354.88
52 Week high$354.88
52 Week low
$230.05
52 Week low$230.05

Stock Snapshot

As of today, Insulet(PODD) shares are valued at $251.22. The company's market cap stands at 17.73B, with a P/E ratio of 74.46.

On 2026-02-04, Insulet(PODD) stock moved within a range of $249.63 to $258.75. With shares now at $251.22, the stock is trading +0.6% above its intraday low and -2.9% below the session's peak.

Trading volume for Insulet(PODD) stock has reached 945.55K, versus its average volume of 1.22M.

Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $230.05.

Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $230.05.

PODD News

TipRanks 8h
Insulet Extends Key Supply Agreement with NXP USA

Insulet ( (PODD) ) just unveiled an update. On January 29, 2026, Insulet Corporation and NXP USA, Inc. entered into a 2026 Addendum, effective January 1, 2026,...

TipRanks 5d
Insulet’s Omnipod M Study Completes Key Milestone in Type 2 Diabetes Onboarding

Insulet (PODD) announced an update on their ongoing clinical study. Study Overview: The trial, formally titled “Feasibility of Simplified Onboarding in Adults...

Analyst ratings

90%

of 30 ratings
Buy
90%
Hold
6.7%
Sell
3.3%

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.